GlaxoSmithKline pay $150 Million in false-Claims case

From Findlaw, GlaxoSmithKline Settles False-Claims Suit for $150 Million:

"Pharmaceutical powerhouse GlaxoSmithKline will pay $150 million to settle a whistle-blower action accusing the company of inflating cancer-drug prices and defrauding the federal Medicare, Medicaid and Tricare programs, according to the U.S. Department of Justice.

The settlement agreement reports that Philadelphia-based GSK denied the allegations but agreed to pay the money and change its drug marketing practices to avoid the expense and inconvenience of litigation."